PMID-21272455 – IFN Plus Thymosin Alpha-1 for HBeAg-Positive HBV: Meta-Analysis
Mao HY, Shi TD. "Treatment with interferon and thymosin alpha-1 versus interferon monotherapy for HBeAg positive chronic hepatitis B: a meta-analysis," Zhonghua Gan Zang Bing Za Zhi, 2011;19(1):29-33. doi:10.3760/cma.j.issn.1007-3418.2011.01.009
Quick Reference
| Property | Value |
|---|---|
| PMID | 21272455 |
| DOI | 10.3760/cma.j.issn.1007-3418.2011.01.009 |
| Year | 2011 |
| Journal | Zhonghua Gan Zang Bing Za Zhi (Chinese Journal of Hepatology) |
| Study Type | Meta-analysis |
| Evidence Level | I |
| Sample | 7 RCTs, n=535 patients with HBeAg-positive chronic hepatitis B |
| Peptide(s) Studied | Thymosin Alpha-1 |
Key Findings
- IFN + Tα1 combination was significantly more effective than IFN alone for HBeAg-positive chronic HBV
- Higher HBV-DNA negativity rate in combination group
- Higher ALT normalization rate
- Higher HBeAg loss/seroconversion rate
- No increase in adverse effects with combination therapy
Study Design
Meta-analysis of 7 RCTs (535 patients) comparing interferon + thymosin alpha-1 combination vs. interferon monotherapy for HBeAg-positive chronic hepatitis B.
Limitations
- Published in Chinese; may have limited international visibility
- All RCTs from China
- Relatively small total sample size (535 patients)
- Published 2011; treatment landscape has evolved
Clinical Relevance
Core evidence supporting ZADAXIN's approved HBV indication in 35+ countries. The combination of antiviral + immunomodulatory therapy (Tα1) is the established treatment approach. Demonstrates Tα1's ability to enhance antiviral immune response when combined with IFN.
Related
#research #meta-analysis #evidence-level-I